AI assistant
BIOLIFE SOLUTIONS INC — Director's Dealing 2022
Jan 7, 2022
32106_dirs_2022-01-06_7c56079c-2ab5-4197-80bc-abcda67479ba.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOLIFE SOLUTIONS INC (BLFS)
CIK: 0000834365
Period of Report: 2022-01-04
Reporting Person: Mathew Aby J. (EVP & Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-01-04 | Common Stock | M | 10000 | $1.40 | Acquired | 216014 | Direct |
| 2022-01-04 | Common Stock | S | 10000 | $35.06 | Disposed | 206014 | Direct |
| 2022-01-05 | Common Stock | M | 7857 | $1.40 | Acquired | 213871 | Direct |
| 2022-01-05 | Common Stock | S | 7857 | $34.30 | Disposed | 206014 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-04 | Employee Stock Option | $1.40 | M | 10000 | Disposed | 2022-02-15 | Common Stock (10000) | Direct |
| 2022-01-05 | Employee Stock Option | $1.40 | M | 7857 | Disposed | 2022-02-15 | Common Stock (7857) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of September 7, 2021.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.59 to $35.33, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.10 to $35.46, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: On February 15, 2012, the reporting person was granted an option to purchase 17,857 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.